vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Maison Solutions Inc. (MSS). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $27.6M, roughly 1.3× Maison Solutions Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -18.0%, a 14.3% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs -10.9%). Over the past eight quarters, Maison Solutions Inc.'s revenue compounded faster (42.5% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
Maison Solutions Inc.MSSEarnings & Financial Report
Maison Solutions Inc. is a specialty home goods retail company that provides a diverse portfolio of stylish, affordably priced furniture, home decor items, and daily household products. Its primary market is the Guangdong-Hong Kong-Macao Greater Bay Area in China, serving mass consumers through both offline physical stores and online e-commerce channels.
GYRE vs MSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $27.6M |
| Net Profit | $-1.4M | $-5.0M |
| Gross Margin | 95.3% | 23.4% |
| Operating Margin | 0.3% | -4.9% |
| Net Margin | -3.7% | -18.0% |
| Revenue YoY | 33.4% | -10.9% |
| Net Profit YoY | -340.1% | -1840.5% |
| EPS (diluted) | $-0.01 | $-0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $27.6M | ||
| Q3 25 | $30.6M | $27.2M | ||
| Q2 25 | $26.8M | $34.4M | ||
| Q1 25 | $22.1M | $32.3M | ||
| Q4 24 | $27.9M | $29.4M | ||
| Q3 24 | $25.5M | $28.2M | ||
| Q2 24 | $25.2M | $16.9M | ||
| Q1 24 | $27.2M | $13.6M |
| Q4 25 | $-1.4M | $-5.0M | ||
| Q3 25 | $5.9M | $-1.5M | ||
| Q2 25 | $1.6M | $-287.4K | ||
| Q1 25 | $3.7M | $1.0M | ||
| Q4 24 | $569.0K | $-256.0K | ||
| Q3 24 | $2.9M | $700.9K | ||
| Q2 24 | $4.5M | $-2.8M | ||
| Q1 24 | $9.9M | $-549.0K |
| Q4 25 | 95.3% | 23.4% | ||
| Q3 25 | 94.7% | 24.1% | ||
| Q2 25 | 95.7% | 9.5% | ||
| Q1 25 | 95.9% | 21.8% | ||
| Q4 24 | 95.8% | 26.9% | ||
| Q3 24 | 96.2% | 28.9% | ||
| Q2 24 | 96.9% | 13.0% | ||
| Q1 24 | 96.4% | 23.4% |
| Q4 25 | 0.3% | -4.9% | ||
| Q3 25 | 22.7% | 0.7% | ||
| Q2 25 | 8.1% | -15.9% | ||
| Q1 25 | 10.3% | 3.7% | ||
| Q4 24 | 2.4% | 3.2% | ||
| Q3 24 | 16.6% | 7.3% | ||
| Q2 24 | 12.7% | -14.4% | ||
| Q1 24 | 29.7% | -2.3% |
| Q4 25 | -3.7% | -18.0% | ||
| Q3 25 | 19.4% | -5.7% | ||
| Q2 25 | 5.9% | -0.8% | ||
| Q1 25 | 16.9% | 3.1% | ||
| Q4 24 | 2.0% | -0.9% | ||
| Q3 24 | 11.2% | 2.5% | ||
| Q2 24 | 18.0% | -16.4% | ||
| Q1 24 | 36.6% | -4.0% |
| Q4 25 | $-0.01 | $-0.23 | ||
| Q3 25 | $0.03 | $-0.08 | ||
| Q2 25 | $0.00 | $-0.02 | ||
| Q1 25 | $0.00 | $0.06 | ||
| Q4 24 | $0.00 | $-0.01 | ||
| Q3 24 | $0.01 | $0.04 | ||
| Q2 24 | $0.01 | $-0.16 | ||
| Q1 24 | $0.03 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | — |
| Total DebtLower is stronger | — | $2.6M |
| Stockholders' EquityBook value | $106.0M | $11.6M |
| Total Assets | $166.1M | $75.4M |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | — | ||
| Q3 25 | $60.0M | $1.1M | ||
| Q2 25 | $54.4M | $775.4K | ||
| Q1 25 | $29.9M | $445.4K | ||
| Q4 24 | $26.7M | $355.7K | ||
| Q3 24 | $25.1M | $588.9K | ||
| Q2 24 | $25.1M | $2.1M | ||
| Q1 24 | $37.4M | $9.4M |
| Q4 25 | — | $2.6M | ||
| Q3 25 | — | $2.6M | ||
| Q2 25 | — | $2.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.5M | ||
| Q2 24 | — | $2.6M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | $106.0M | $11.6M | ||
| Q3 25 | $101.9M | $10.1M | ||
| Q2 25 | $92.0M | $11.7M | ||
| Q1 25 | $68.1M | $12.0M | ||
| Q4 24 | $63.3M | $10.9M | ||
| Q3 24 | $63.2M | $11.2M | ||
| Q2 24 | $60.4M | $10.5M | ||
| Q1 24 | $56.6M | $13.3M |
| Q4 25 | $166.1M | $75.4M | ||
| Q3 25 | $159.4M | $73.3M | ||
| Q2 25 | $152.6M | $77.4M | ||
| Q1 25 | $129.8M | $82.7M | ||
| Q4 24 | $125.4M | $82.7M | ||
| Q3 24 | $125.2M | $82.1M | ||
| Q2 24 | $120.9M | $82.4M | ||
| Q1 24 | $122.0M | $44.2M |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | 0.22× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.24× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $-1.7M |
| Free Cash FlowOCF − Capex | $-5.8M | — |
| FCF MarginFCF / Revenue | -15.5% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $-1.7M | ||
| Q3 25 | $4.7M | $1.1M | ||
| Q2 25 | $2.1M | $-1.6M | ||
| Q1 25 | $-129.0K | $1.7M | ||
| Q4 24 | $-2.8M | $1.1M | ||
| Q3 24 | $1.7M | $3.6M | ||
| Q2 24 | $-5.5M | $-2.6M | ||
| Q1 24 | $2.9M | $-1.4M |
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-251.0K | — | ||
| Q4 24 | $-2.8M | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $-6.9M | — | ||
| Q1 24 | $2.7M | — |
| Q4 25 | -15.5% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | -1.1% | — | ||
| Q4 24 | -10.1% | — | ||
| Q3 24 | 4.1% | — | ||
| Q2 24 | -27.5% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 2.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 0.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.03× | 1.66× | ||
| Q4 24 | -4.85× | — | ||
| Q3 24 | 0.60× | 5.12× | ||
| Q2 24 | -1.21× | — | ||
| Q1 24 | 0.29× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GYRE
Segment breakdown not available.
MSS
| Perishables | $14.4M | 52% |
| Nonperishables | $13.2M | 48% |
